Patents Assigned to UNIVERSITY OF ZÜRICH
-
Patent number: 12217417Abstract: Systems/techniques that facilitate learning-based domain transformation for medical images are provided. In various embodiments, a system can access a medical image. In various aspects, the medical image can depict an anatomical structure according to a first medical scanning domain. In various instances, the system can generate, via execution of a machine learning model, a predicted image based on the medical image. In various aspects, the predicted image can depict the anatomical structure according to a second medical scanning domain that is different from the first medical scanning domain. In some cases, the first and second medical scanning domains can be first and second energy levels of a computed tomography (CT) scanning modality. In other cases, the first and second medical scanning domains can be first and second contrast phases of the CT scanning modality.Type: GrantFiled: September 9, 2021Date of Patent: February 4, 2025Assignees: GE PRECISION HEALTHCARE LLC, UNIVERSITY OF ZURICHInventors: Sidharth Abrol, Bipul Das, Vanika Singhal, Amy Deubig, Sandeep Dutta, Daphné Gerbaud, Bianca Sintini, Ronny Büchel, Philipp Kaufmann
-
Publication number: 20230255156Abstract: The present invention relates to maize plants having increased pathogen resistance or tolerance, in particular increased resistance or tolerance to pathogens causing Northern Corn Leaf Blight, i.e. Exserohilum turcicum. Such maize plants are characterized by particular molecular markers The invention further relates to methods for identifying such maize plants.Type: ApplicationFiled: July 14, 2021Publication date: August 17, 2023Applicants: KWS SAAT SE & Co. KGaA, UNIVERSITY OF ZURICHInventors: Daniela SCHEUERMANN, Milena OUZUNOVA, Bettina KESSEL, Beat KELLER, Ping YANG
-
Publication number: 20230242643Abstract: Chimeric antigen receptor (CAR) bridging protein are provided comprising a CAR-binding domain linked to an antigen-binding domain, which can be used to re-direct the targeting of CAR-T cells. The bridging protein may comprie an antigen-binding domain that targets any antigen of interest, such as, for example, a tumor antigen or viral antigen. Also provided are methods of using the bridging proteins in combination with CAR-T cells to treat a disease, such as, for example, a cancer or an infectious disease.Type: ApplicationFiled: May 27, 2021Publication date: August 3, 2023Applicants: ANTION BIOSCIENCES SA, GENEVA UNIVERSITY HOSPITALS, UNIVERSITY OF GENEVA, UNIVERSITY OF ZURICHInventors: Marco ALESSANDRINI, Karl-Heinz KRAUSE, Renier MYBURGH
-
Patent number: 11649455Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.Type: GrantFiled: April 1, 2019Date of Patent: May 16, 2023Assignees: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICHInventors: Karl-Heinz Krause, Francis Rousset, Patrick Salmon, Marco Alessandrini, Roberto Speck, Simon Bredl, Tafadzwa Mlambo, Renier Myburgh
-
Patent number: 11613747Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.Type: GrantFiled: April 1, 2019Date of Patent: March 28, 2023Assignees: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICHInventors: Karl-Heinz Krause, Francis Rousset, Patrick Salmon, Marco Alessandrini, Roberto Speck, Simon Bredl, Tafadzwa Mlambo, Renier Myburgh
-
Publication number: 20230070984Abstract: The present invention relates to compositions comprising gases, particularly oxygen (O2) in an amount of from about 91% to about 99% by volume, and carbon dioxide (CO2) in an amount of from about 1% to about 9% by volume, based upon the total volume of the composition, and their use in mitigating the negative effects of surgery and/or anaesthesia on a patient.Type: ApplicationFiled: February 18, 2021Publication date: March 9, 2023Applicants: AVIATION WORKS LIMITED, UNIVERSITY OF ZURICHInventors: Marc STUDER, Simisola OKE, Rob BOYLE, Beatrice Beck SCHIMMER, Martin SCHLÄPFER
-
Publication number: 20230021982Abstract: The present invention relates to methods for producing plants with increased fungal resistance, preferably seedling resistance against Northern Corn Leaf Blight. Further provided are methods for introducing, modifying, or modulating at least one wall-associated kinase (WAK) in(to) a plant cell, tissue, organ, or whole plant and thereby causing a reduced synthesis of benzoxazinoid and in turn increased fungal resistance. There are further provided methods to identify and/or modify downstream effector molecules in a WAK signalling cascade. Finally, plant cells, tissues, organs or whole plants having increased fungal resistance and methods using substances to activate signalling pathways in a targeted way are provided.Type: ApplicationFiled: August 25, 2022Publication date: January 26, 2023Applicants: KWS SAAT SE & Co. KGaA, UNIVERSITY OF ZURICH, UNIVERSITY OF BERNInventors: Bettina KESSEL, Milena OUZUNOVA, Daniela SCHEUERMANN, Beat KELLER, Simon KRATTINGER, Coraline PRAZ, Ping YANG, Matthias ERB
-
Patent number: 11352441Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: May 28, 2019Date of Patent: June 7, 2022Assignees: NEURIMMUNE HOLDING AG, UNIVERSITY OF ZURICHInventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan Mcafoose, Marcel Maier
-
Publication number: 20210095278Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.Type: ApplicationFiled: April 1, 2019Publication date: April 1, 2021Applicants: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICHInventors: Karl-Heinz KRAUSE, Francis ROUSSET, Patrick SALMON, Marco ALESSANDRINI, Roberto SPECK, Simon BREDL, Tafadzwa MLAMBO, Renier MYBURGH
-
Patent number: 10870887Abstract: Described are methods and kits for identifying a subject at risk of, or having, a sensory neuropathy related disease, such as sensory neuropathies. In particular, the disclosure is based on the determination of mutations in the SPTLC2 gene causing sensory neuropathies.Type: GrantFiled: November 16, 2017Date of Patent: December 22, 2020Assignees: VIB VZW, UNIVERSITEIT ANTWERPEN, UNIVERSITY OF ZURICH, MEDICAL UNIVERSITY OF GRAZInventors: Annelies Rotthier, Vincent Timmerman, Michaela Auer-Grumbach, Thorsten Hornemann
-
Patent number: 10858429Abstract: The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotixin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.Type: GrantFiled: January 7, 2016Date of Patent: December 8, 2020Assignee: UNIVERSITY OF ZURICHInventors: Uwe Zangemeister-Wittke, Claudio Di Paolo, Dominique Christine Tschudi, Nicholas Ronald Glover, Dimitri Peter Fitsialos
-
Patent number: 10344097Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: February 3, 2016Date of Patent: July 9, 2019Assignees: NEURIMMUNE HOLDING AG, UNIVERSITY OF ZURICHInventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan Mcafoose, Marcel Maier
-
Patent number: 10202445Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: GrantFiled: May 12, 2017Date of Patent: February 12, 2019Assignee: UNIVERSITY OF ZURICHInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Publication number: 20180155790Abstract: Described are methods and kits for identifying a subject at risk of, or having, a sensory neuropathy related disease, such as sensory neuropathies. In particular, the disclosure is based on the determination of mutations in the SPTLC2 gene causing sensory neuropathies.Type: ApplicationFiled: November 16, 2017Publication date: June 7, 2018Applicants: VIB VZW, UNIVERSITEIT ANTWERPEN, UNIVERSITY OF ZURICH, MEDICAL UNIVERSITY OF GRAZInventors: Annelies Rotthier, Vincent Timmerman, Michaela Auer-Grumbach, Thorsten Hornemann
-
Patent number: 9744336Abstract: Device for gravity-driven, particularly continuous, control of the filling pressure in a balloon catheter (3), comprising: a balloon reservoir that is statically loaded with a vertically guided weight guide or stamp (9) that weighs vertically on the balloon reservoir, wherein said weight guide or stamp is designed to carry vertically arranged and therewith plumb-vertically acting weight elements (8), and wherein the balloon reservoir is guided in a cylindrical shell (6).Type: GrantFiled: March 22, 2013Date of Patent: August 29, 2017Assignee: UNIVERSITY OF ZURICHInventor: Andreas Christian Gerber
-
Patent number: 9670272Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: GrantFiled: December 17, 2012Date of Patent: June 6, 2017Assignee: UNIVERSITY OF ZURICHInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 9642898Abstract: The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.Type: GrantFiled: November 21, 2014Date of Patent: May 9, 2017Assignees: MED DISCOVERY S.A., UNIVERSITY OF ZURICHInventors: Adriano Fontana, Mike Recher, Christoph Kundig
-
Patent number: 9642872Abstract: The invention relates to microRNA-34a and related microRNAs for use in the treatment of B-cell lymphoma. Likewise it relates to microRNA-34a for use in the preparation of a medicament for the treatment of B-cell lymphoma, and for a method of treatment of B-cell lymphoma comprising administering microRNA-34a. These claims are based on the observation that microRNA-34a shows strong anti-proliferative effects when overexpressed in diffuse large B-cell lymphoma (gDLBCL) cell lines, or when delivered intratumorally or systemically in xenograft models of DLBCL.Type: GrantFiled: December 9, 2014Date of Patent: May 9, 2017Assignee: UNIVERSITY OF ZURICHInventors: Vanessa Craig, Anne Mueller
-
Patent number: 9512156Abstract: The present invention relates to new rhenium compounds of formula (I) with medical utility, corresponding pharmaceutical compositions as well as medical uses thereof.Type: GrantFiled: March 4, 2011Date of Patent: December 6, 2016Assignee: UNIVERSITY OF ZURICHInventors: Fabio Zobi, Roger Alberto, Lukas Kromer
-
Patent number: 9512202Abstract: The invention relates to a method for isolating a polypeptide reactive to influenza A hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of said library is attached to a polypeptide sequence encoded thereby, selecting members of said library by contacting the members with a panning antigen, wherein the panning antigen comprises a hemagglutinin stem region polypeptide sequence, subsequently removing members unreactive to the panning antigen, and selecting a member of said library by determining its binding to at least 5 influenza A hemagglutinin subtypes of subtype group 1 and 2. The invention further relates to polypeptides, particularly antibodies, obtainable by this method, that neutralize at least five influenza A subtypes of subtype group 1 and 2, to vaccines and uses thereof.Type: GrantFiled: August 27, 2012Date of Patent: December 6, 2016Assignee: UNIVERSITY OF ZURICHInventors: Lars Hangartner, Arkadiusz Wyrzucki